---
title: "Can Komzifti's Early Adoption Support Kura Oncology's Next Phase Of Growth?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296928079.md"
description: "Kura Oncology demonstrates strong early market traction for its acute myeloid leukemia (AML) therapy, securing a leading position in the menin inhibitor class within its second full quarter post-launch. The company has captured the majority of new patient starts, highlighting that patient adoption is crucial for commercial success beyond FDA approval."
datetime: "2026-08-25T14:13:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296928079.md)
  - [en](https://longbridge.com/en/news/296928079.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296928079.md)
generator: "portal-rs"
---

# Can Komzifti's Early Adoption Support Kura Oncology's Next Phase Of Growth?

Add  as your preferred news source on Google

 Add Now

FDA approval is an important milestone, but it is patient adoption that ultimately determines a therapy's commercial success. 

The company we are profiling today has shown strong early market traction, securing a leading position in the menin inhibitor class within just its second full quarter after launching its acute myeloid leukemia (AML) therapy and capturing the majority of new patient starts.

This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.

Start Free Trial

FREE 7-Day Trial - No Payment Required

Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [KURA.US](https://longbridge.com/en/quote/KURA.US.md)

## Related News & Research

- [Kura Oncology to Participate in Three Investor Conferences in September | KURA Stock News](https://longbridge.com/en/news/297643143.md)
- [Kura Oncology Chief Commercial Officer Brian T. Powl sells 4,345 common shares for USD 51,656.85](https://longbridge.com/en/news/296831179.md)
- [eDreams ODIGEO Beats Market Estimates One Quarter Into Its Peak Investment Year and Further Grows Subscribers to 8.1 Million | EDDRF Stock News](https://longbridge.com/en/news/297623101.md)
- [Rubrik Q2 revenue jumps 38% on subscription ARR growth](https://longbridge.com/en/news/297228242.md)
- [Apple TV now costs $14.99 a month after its fourth price hike in four years](https://longbridge.com/en/news/297336208.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**